Fidelity Disruptive Medicine ETF $FMED Stock Holdings Increased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC raised its position in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) by 4.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 714,991 shares of the company’s stock after buying an additional 31,629 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.31% of Fidelity Disruptive Medicine ETF worth $19,712,000 at the end of the most recent quarter.

Separately, Jane Street Group LLC grew its position in shares of Fidelity Disruptive Medicine ETF by 0.8% in the 1st quarter. Jane Street Group LLC now owns 66,382 shares of the company’s stock worth $1,567,000 after acquiring an additional 499 shares in the last quarter.

Fidelity Disruptive Medicine ETF Trading Up 1.8%

Shares of NASDAQ FMED opened at $24.39 on Thursday. The company has a market capitalization of $56.10 million, a price-to-earnings ratio of 41.33 and a beta of 1.00. Fidelity Disruptive Medicine ETF has a twelve month low of $20.69 and a twelve month high of $29.07. The business has a 50 day simple moving average of $25.91 and a 200-day simple moving average of $26.35.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.